BTN3A1/CD277, His & Avi, Cynomolgus
| $390.00 | |
| Z04754-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $390.00 | |
| Z04754-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Cynomolgus | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 26.5 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 30-35 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized BTN3A1/CD277, His & Avi, Cynomolgus, His Tag at 2 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-BTN3A1 Antibody, hFc Tag with the EC50 of 6.4ng/ml determined by ELISA. »
The purity of BTN3A1/CD277, His & Avi, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
BTN3A1/CD277, His & Avi, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The three butyrophilin BTN3A molecules, BTN3A1, BTN3A2, and BTN3A3, are members of the B7/butyrophilin-like group of Ig superfamily receptors, which modulate the function of T cells. BTN3A1 controls activation of human Vγ9/Vδ2 T cells by direct or indirect presentation of self and nonself phosphoantigens (pAg). |
| Synonyms | CD277; BTN3A1; BTF5; BT3.1; BTN3.1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.